We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Geospiza and PSC Collaborates to Accelerate the Development of Genetic Tests and Personalized Treatments
News

Geospiza and PSC Collaborates to Accelerate the Development of Genetic Tests and Personalized Treatments

Geospiza and PSC Collaborates to Accelerate the Development of Genetic Tests and Personalized Treatments
News

Geospiza and PSC Collaborates to Accelerate the Development of Genetic Tests and Personalized Treatments

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Geospiza and PSC Collaborates to Accelerate the Development of Genetic Tests and Personalized Treatments"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Geospiza and Pharmaceutical Services Corporation (PSC) have announced an alliance to deliver software and services to manufacturers of personalized therapies and vaccines based on genetic markers.

Under the terms of the agreement, PSC will offer a complete solution of Geospiza software and PSC services to reduce operational costs and regulatory risks for organizations that need to integrate genetic analyses into their manufacturing process.

“Manual genetic analysis continues to be a major bottleneck for companies trying to bring new and innovative genetic tests and personalized treatments to market,” said Rob Arnold, president of Geospiza.

“Geospiza and PSC are committed to helping our clients manage the regulatory requirements of genetic analysis automation in a full-scale commercial environment,” Arnold added.

“We are approaching this market together because the biotech, pharmaceutical and diagnostic industries are at a true inflection point,” said Patricia Rossman, Vice President of Pharmaceutical Services Corporation. “PSC and Geospiza share a common vision for delivery excellence.”

PSC will target the combined offering to manufacturers of vaccines, novel bio-therapeutics and gene therapies which are regulated by U.S. Food and Drug Administration (FDA) requirements for aseptic processing for the manufacture of sterile drug and biological products under current Good Manufacturing Practice (cGMP) regulations (21 CFR parts 210 and 211).

Facilities and agencies involved in environmental monitoring, food safety testing, molecular diagnostic testing and clinical trial efforts expected to benefit as well.

Advertisement